Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974343 | 0.94 | LMNA (0.51) | SMN1; SMN2HTTLMNARECQLGPR132 | |
| SCHEMBL4497230 | 0.89 | HTT (0.55) | SMN1; SMN2HTTLMNARECQLGPR132 | |
| SCHEMBL4061701 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2HTTLMNARECQLGPR132 | |
| SCHEMBL2961360 | 0.86 | HPGD (0.44) | SMN1; SMN2MAPTALDH1A1NPC1MEN1 | |
| SCHEMBL2972987 | 0.84 | GAA (0.62) | SMN1; SMN2LMNAMAPK1POLBMAPT | |
| SCHEMBL2975296 | 0.84 | RIPK1 (0.47) | SMN1; SMN2ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2970729 | 0.84 | HPGD (0.47) | SMN1; SMN2LMNAMAPK1MAPTALDH1A1 | |
| SCHEMBL1379465 | 0.83 | LMNA (0.53) | SMN1; SMN2HTTLMNARECQLGPR132 | |
| SCHEMBL2973781 | 0.82 | ALOX5 (0.47) | SMN1; SMN2ALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL4066415 | 0.82 | GPR132 (0.46) | SMN1; SMN2HTTLMNARECQLGPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658289-B1 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARM INC (US) | 2009-03-18 | — | — | EP | claimed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | claimed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | claimed |
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1658289-B1 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARM INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-7442709-B2 | N3-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | disclosed |
| EP-1658289-A2 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | disclosed |
| WO-2005021544-A2 | N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | KIT, ABL1, CHUK | SMN1; SMN2 2602/4885HTT 4484/4885LMNA 2735/4885 |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | KIT, ABL1, CHUK | SMN1; SMN2 2471/4885HTT 4453/4885LMNA 2633/4885 |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | KIT, ABL1, CHUK | SMN1; SMN2 2471/4885HTT 4453/4885LMNA 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.